Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic Kidney Disease-associated pruritus (CKD-aP) is a debilitating and frequently under-recognised symptom that is associated with insomnia, depression, poor health-related quality of life and increased mortality. Treatment of refractory CKD-aP in patients with advanced chronic kidney disease (CKD) on a conservative kidney management (CKM) pathway can be challenging due to its incompletely understood pathophysiology. Treatment algorithms are not well defined when patients are unresponsive to traditional oral or topical therapies. Furthermore, CKM patients have difficulty accessing intravenous difelikefalin, which is only approved for haemodialysis patients. The evidence for use of subcutaneous lidocaine in CKD-aP is limited and to our knowledge there have been no data on conservatively managed CKD patients.
We herein report a case of a 59-year-old male with background of CKD secondary to diabetic nephropathy and Korsakoff Dementia on a non-dialytic CKM pathway who presented with severe CKD-aP exhibiting diffuse excoriation with areas of bleeding though no associated rash. His creatinine was 495umol/L, eGFR 10ml/min/1.73m2 and he scored 10/10 on the Visual Analogue Scale (VAS) for pruritus severity. Other skin conditions were excluded following dermatology review and multiple therapies had been trialled, including regular aqueous emollients, topical capsaicin, pregabalin (up to doses of 150mg BD), methylprednisone 0.1% ointment, sertraline, evening primrose oil and doxepin. Subcutaneous lidocaine infusion was trialled given the refractory nature of his pruritus at a starting dose of 400mg over 24-hours via syringe driver. The dose was gradually up-titrated to 600mg over 10-days and QTc was monitored with no evidence of toxicity.
There was marked improvement in the appearance of his skin and healing of the diffuse excoriation over a period of 4 weeks. This was documented on sequential photographs demonstrating evidence of healing and resolution of the severe excoriation. His reported pruritus severity decreased to 6/10 on the VAS over 3-4 days and subsequently to 4/10 after another 7 days. No side-effects were observed. The response was sustained for 6 weeks, after which the patient deteriorated from underlying kidney failure and end of life care was provided.
Subcutaneous lidocaine infusion may be an effective and safe alternative treatment option for cases of refractory CKD-aP.
